VERONA, Italy, June 1, 2012 /CNW/ - CROMSOURCE, an international full
service contract research organisation (CRO) today announced the
acquisition of Pleiad, an established international CRO with offices in
the US (Cambridge, Mass.) and UK (Stirling, Scotland).
Pleiad was launched in 1999, supporting clients in multiple therapy
areas and with dedicated Medical Device and Ophthalmology Divisions.
Additionally, Pleiad also encompasses particularly strong capabilities
within statistics and data management.
'We are delighted to welcome Pleiad and its expert team', stated Dr
Oriana Zerbini, Chief Executive Officer of CROMSOURCE. 'For some time
we have wanted to expand and consolidate our presence in the US and we
have now found the perfect way to do so. The opportunity to further add
to our UK team and expand our team of experts in data management and
statistics is also of great importance to us. With this collaboration
CROMSOURCE reinforces its capability to support our clients with even
the largest of development programmes in both Europe and the USA.'
Dr Helen Colquhoun, CEO of Pleiad, noted 'with CROMSOURCE we share a
philosophy of quality, flexibility and intense customer focus. We are
therefore very excited to be joining the CROMSOURCE family and working
together to provide exceptional service to our current and future
About CROMSOURCE: CROMSOURCE is an ISO certified, full-service Contract
Research Organization providing clinical trial services and staffing
solutions since 1994. CROMSOURCE delivers clinical trials across
Europe, Russia, Ukraine and the USA and operates a high quality early
phase unit. CROMSOURCE provides One Trial One Price - a fixed price
guarantee which assures clients that each project will be delivered
according to the contract price.
For further information:
Via Scuderlando, 10
37135 Verona, Italy